These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 19091564)
1. Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 7: syntheses and opioid receptor properties of cyclic variants of cyclazocine. Wentland MP; Lu Q; Ganorkar R; Zhang SZ; Jo S; Cohen DJ; Bidlack JM Bioorg Med Chem Lett; 2009 Jan; 19(2):365-8. PubMed ID: 19091564 [TBL] [Abstract][Full Text] [Related]
2. Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. 4. Opioid receptor binding properties of 8-[N-(4'-phenyl)-phenethyl)carboxamido] analogues of cyclazocine and ethylketocycalzocine. Wentland MP; VanAlstine M; Kucejko R; Lou R; Cohen DJ; Parkhill AL; Bidlack JM J Med Chem; 2006 Sep; 49(18):5635-9. PubMed ID: 16942039 [TBL] [Abstract][Full Text] [Related]
3. Syntheses and opioid receptor binding affinities of 8-amino-2,6-methano-3-benzazocines. Wentland MP; Ye Y; Cioffi CL; Lou R; Zhou Q; Xu G; Duan W; Dehnhardt CM; Sun X; Cohen DJ; Bidlack JM J Med Chem; 2003 Feb; 46(5):838-49. PubMed ID: 12593663 [TBL] [Abstract][Full Text] [Related]
4. Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 6: Opioid receptor binding properties of cyclic variants of 8-carboxamidocyclazocine. Wentland MP; Sun X; Cohen DJ; Bidlack JM Bioorg Med Chem; 2008 May; 16(10):5653-64. PubMed ID: 18417347 [TBL] [Abstract][Full Text] [Related]
5. Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. 5. Opioid receptor binding properties of N-((4'-phenyl)-phenethyl) analogues of 8-CAC. VanAlstine MA; Wentland MP; Cohen DJ; Bidlack JM Bioorg Med Chem Lett; 2007 Dec; 17(23):6516-20. PubMed ID: 17935988 [TBL] [Abstract][Full Text] [Related]
7. Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 3: 8-Thiocarboxamido and 8-thioformamido derivatives of cyclazocine. Wentland MP; Sun X; Bu Y; Lou R; Cohen DJ; Bidlack JM Bioorg Med Chem Lett; 2005 May; 15(10):2547-51. PubMed ID: 15863314 [TBL] [Abstract][Full Text] [Related]
8. Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 2: 8-formamidocyclazocine analogues. Wentland MP; Sun X; Ye Y; Lou R; Bidlack JM Bioorg Med Chem Lett; 2003 Jun; 13(11):1911-4. PubMed ID: 12749896 [TBL] [Abstract][Full Text] [Related]
9. Elucidation of the bioactive conformation of the N-substituted trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine class of mu-opioid receptor antagonists. Le Bourdonnec B; Goodman AJ; Michaut M; Ye HF; Graczyk TM; Belanger S; Herbertz T; Yap GP; DeHaven RN; Dolle RE J Med Chem; 2006 Dec; 49(25):7278-89. PubMed ID: 17149858 [TBL] [Abstract][Full Text] [Related]
10. Synthesis and pharmacological evaluation of novel octahydro-1H-pyrido[1,2-a]pyrazine as mu-opioid receptor antagonists. Le Bourdonnec B; Goodman AJ; Graczyk TM; Belanger S; Seida PR; DeHaven RN; Dolle RE J Med Chem; 2006 Dec; 49(25):7290-306. PubMed ID: 17149859 [TBL] [Abstract][Full Text] [Related]
11. Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 8. High affinity ligands for opioid receptors in the picomolar Ki range: oxygenated N-(2-[1,1'-biphenyl]-4-ylethyl) analogues of 8-CAC. Wentland MP; Jo S; Gargano JM; VanAlstine MA; Cohen DJ; Bidlack JM Bioorg Med Chem Lett; 2012 Dec; 22(24):7340-4. PubMed ID: 23142613 [TBL] [Abstract][Full Text] [Related]
12. [35S]GTPgammaS binding at the human dopamine D4 receptor variants hD4.2, hD4.4 and hD4.7 following stimulation by dopamine, epinephrine and norepinephrine. Czermak C; Lehofer M; Liebmann PM; Traynor J Eur J Pharmacol; 2006 Feb; 531(1-3):20-4. PubMed ID: 16423344 [TBL] [Abstract][Full Text] [Related]
13. 8-Carboxamidocyclazocine analogues: redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Wentland MP; Lou R; Ye Y; Cohen DJ; Richardson GP; Bidlack JM Bioorg Med Chem Lett; 2001 Mar; 11(5):623-6. PubMed ID: 11266156 [TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 1. Takeuchi K; Holloway WG; McKinzie JH; Suter TM; Statnick MA; Surface PL; Emmerson PJ; Thomas EM; Siegel MG; Matt JE; Wolfe CN; Mitch CH Bioorg Med Chem Lett; 2007 Oct; 17(19):5349-52. PubMed ID: 17720493 [TBL] [Abstract][Full Text] [Related]
15. Synthesis and pharmacological characterization of a novel, highly potent, peptidomimetic delta-opioid radioantagonist, [3H]Tyr-Tic-(2S,3R)-beta-MePhe-Phe-OH. Birkas E; Kertesz I; Toth G; Bakota L; Gulya K; Szucs M Neuropeptides; 2008 Feb; 42(1):57-67. PubMed ID: 18068762 [TBL] [Abstract][Full Text] [Related]
16. Fancy bioisosteres: metallocene-derived G-protein-coupled receptor ligands with subnanomolar binding affinity and novel selectivity profiles. Schlotter K; Boeckler F; Hübner H; Gmeiner P J Med Chem; 2005 Jun; 48(11):3696-9. PubMed ID: 15916420 [TBL] [Abstract][Full Text] [Related]
18. Structure-activity relationships of dynorphin analogs substituted in positions 2 and 3. Schlechtingen G; DeHaven RN; Daubert JD; Cassel J; Goodman M Biopolymers; 2003; 71(1):71-6. PubMed ID: 12712501 [TBL] [Abstract][Full Text] [Related]
19. Unpredictable stereochemical preferences for mu opioid receptor activity in an exhaustively stereodiversified library of 1,4-enediols. Shi Z; Harrison BA; Verdine GL Org Lett; 2003 Mar; 5(5):633-6. PubMed ID: 12605477 [TBL] [Abstract][Full Text] [Related]
20. [35S]GTPgammaS binding in G protein-coupled receptor assays. Cooper T; McMurchie EJ; Leifert WR Methods Mol Biol; 2009; 552():143-51. PubMed ID: 19513647 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]